Loading...
XHKG
0690
Market cap87mUSD
Dec 05, Last price  
0.11HKD
1D
0.89%
1Q
-31.52%
Jan 2017
-26.14%
IPO
-92.25%
Name

Uni-Bio Science Group Ltd

Chart & Performance

D1W1MN
XHKG:0690 chart
P/E
8.21
P/S
1.23
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
-0.45%
Rev. gr., 5y
21.43%
Revenues
553m
+14.08%
94,949,000340,894,000869,946,000526,270,000148,286,00076,764,00057,026,00083,333,000102,624,000122,390,636123,364,000146,489,000156,477,000135,258,000209,449,000208,776,000353,405,000440,316,000484,718,000552,980,000
Net income
83m
+16.79%
-42,160,00060,316,000198,380,000-508,323,000-454,653,000-185,156,000-102,864,000-69,308,000-366,130,000-56,578,653-59,799,000-55,727,000-279,309,000-138,567,0002,459,000-71,319,000-19,591,00038,512,00070,876,00082,774,000
CFO
67m
-32.52%
-705,00086,804,00091,214,00073,542,00081,148,000-29,983,000-37,508,000-20,243,00049,991,000-79,702,647-12,595,000-23,691,000-68,605,000-89,000,000-30,749,000-15,474,00012,042,00048,660,00098,849,00066,708,000
Dividend
Aug 22, 20070.00157 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.
URL
https://www.uni-bioscience.com/
IPO date
Nov 12, 2001
Employees
340
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT